InterMune to Release First Quarter 2006 Financial Results on April 27 (Hep C Treatment)

InterMune to Release First Quarter 2006 Financial Results on April 27
[Press Release] PR Newswire via Yahoo! Finance - Apr 06 1:01 PM
InterMune, Inc. today announced that it will release first quarter 2006 financial results on Thursday, April 27, 2006 at 4:00 p.m. ET.Save to My Web

New report on carcinogens adds seventeen substances
Enviornmental News Link - Apr 05 10:12 PM
RESEARCH TRIANGLE PARK, NC (02/04/05) -- The recently released Eleventh Edition of the Report on Carcinogens adds seventeen substances to the growing list of cancer-causing agents, bringing the total to 246.Save to My Web

Coley Pharmaceutical Group Announces Top-line Data from a Clinical Study of Actilon(TM) for Hepatitis C
[Press Release] PR Newswire via Yahoo! Finance - Mar 21 5:30 AM
Coley Pharmaceutical Group, Inc. today announced positive top-line interim data from the company's twelve-week, randomized, controlled clinical study of Actilon in combinations with pegylated interferon and/or ribavirin for the treatment of chronic Hepatitis C virus in the relapsed subset of treatment experienced patients.Save to My Web

Rigel Granted Key Patents in Immunology, Virology and Oncology
[Press Release] PR Newswire via Yahoo! Finance - Mar 21 4:30 AM
Rigel Pharmaceuticals, Inc. today announced that it has been awarded 29 patents since February 2004. Specifically, Rigel was granted six patents in immunology, five patents related to its ubiquitin ligase technology, four patents related to hepatitis-C , six patents in oncology, four patents towards its library screening technology, and four patents in Fluorescence- Activated Cell Sorter Save to My Web

USLS Silay spikers triumph in NOVA-NOCSF volleyfest
Sun Star - Mar 21 7:57 PM
SILAY City spikers and their counterparts from host University of St. La Salle extended their winning runs last weekend in the ongoing l6th Negros Occidental Volleyball Association (NOVA)-Negros Occidental Cultural and Sports Foundation (NOCSF) Age-Group Volleyball Championship at the USLS covered courts.Save to My Web

Staff Writer
BioWorld - Mar 29 9:10 PM
Despite a decision last week by Idenix Pharmaceuticals Inc. to reduce dosing levels to avoid gastrointestinal side effects of its hepatitis C Phase IIb drug candidate, NM283 - a move that drove the companys stock down by 28.3 percent - partner Novartis AG exercised its option to license the product anyway in a deal worth up to $525 million.Save to My Web